Clinical Pharmacology Group Head - Anti-infectives, Early Clinical Development Pfizer Groton, Connecticut
The attendees will learn about the implementation of alternative strategy of 19F-NMR for ADME characterization to support accelerated development of PAXLOVID. Such approach can provide the data much early in drug development without a need of radioactive material. The attendees will also learn advantages and potential challenges of implementation of this approach.
Learning Objectives:
to understand implementation of alternative strategy for ADME characterization of PAXLOVID
to describe the mass balance and metabolic profile of PAXLOVID
to implement 19F-NMR based ADME characterization to other drugs
